UPClytics
View all cases

UPC APP 25212/2025

EP2279254 +1 more · NOVEL LIPID FORMULATIONS FOR NUCLEIC ACID DELIVERY

Case details
Status
—
Action
Procedural application
Category
Other procedural
Parties
Claimants
Representatives
  • Markus van Gardingen
Respondents
Representatives
  • Ruben Laddé
  • Joachim Renken
Patents
Division
The Hague LD
Technology
  • Chemistry
    Pharmaceuticals · Biotechnology
Language
—
First decided
Jun 4, 2025
EPO Opposition
  • Merck Sharp & Dohme CorporationAdmissible2018-04-05
  • Moderna Therapeutics, Inc.Admissible2018-04-05
  • Merck Sharp & Dohme LLCWithdrawn2018-04-05
  • ModernaTX, Inc.Withdrawn2018-04-05
  • ModernaTX, Inc.Withdrawn2025-04-29
  • Merck Sharp & Dohme (UK) LimitedWithdrawn2025-07-23
  • Arrowhouse GmbHAdmissible2025-07-23
  • Keltie LLPAdmissible2025-07-23
How this compares
How long the court takes to reach a first decision.
Median days to first decision
All UPC124
The Hague LDLocked
Judge Margot KokkeLocked

At the UPC: Genevant Sciences GmbH (9 cases)·Moderna Group (20 cases)

Related cases

This dispute contains 6 other proceedings

UPC CFI 617/2025·UPC CFI 607/2025·UPC CFI 191/2025·UPC CFI 192/2025·UPC APP 18039/2025 and 1 more

2 other defendants litigating the same or a related patent

UPC CFI 2562/2026·UPC CFI 2566/2026

Start a free trial to see how each one ended.

More cases: The Hague LD·2025

Decisions
  • 2025-06-04

    Summary: The Hague Local Division issued a rectification order under R.353 RoP correcting clerical errors in a prior procedural order regarding the dates of service on Moderna Germany, Belgium, and Poland, thereby rendering Moderna's preliminary objections admissible for all defendants in infringement actions concerning EP2279254 and EP4241767.

    Show the legal issues (4)
    • Rectification of order (R.353 RoP)
    • Clerical errors in date of service
    • Admissibility of preliminary objections
    • Time limit for preliminary objections
Documents
  • 3A6CB666B2346F48F42C2C1ED8EB1D9B_en.pdf2025-06-04EN